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SUMMARY — Two patients with cryptococcosis of the CNS were treated with ketoconazole 
(KTZ), an imidazole derivative with fungistatic properties; they had either failed standard 
therapy (Amphotericin-B + 5-Flurocytosine) or suffred intolerable side-effects to it. Both 
patients were administered KTZ 800 mg/day as monotherapy for six months without interrup-
tion and both responded. One month after KTZ therapy was withdrawn, however, a relapse 
of the infection was seen in one case. Side-effects were minimal during the trial of treatment. 
KTZ could be a useful drug in some cases of neurocryptococcosis. 
Ketoconazole no tratamento da neurocriptococose 
RESUMO — Dois pacientes com neurocriptococose foram tratados com ketoconazole (KTZ), um 
derivado imidazólico de propriedades fungostáticas. Ambos foram tratados inicialmente com o 
esquema terapêutico tradicional (anfotericina-B + 5-flurocitosina) porém em um dos casos 
para-efeitos intoleráveis obrigaram a suspensão do tratamento e, no outro caso, não houve 
resposta ao esquema terapêutico. KTZ foi administrado regularmente por via oral em regime 
de monoterapia na dose de 800mg diárias durante 6 meses com ótimos resultados. Todavia, 
um mês após a suspensão do tratamento, houve recorrência da infecção em um paciente. Efei-
tos colaterais foram mínimos durante o curso do tratamento. KTZ pode ser útil no trata-
mento de alguns casos de neurocriptococose. 
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Cryptococcosis is a rare but grievous affliction caused by the fungus Crypto-
coccus neoformans, an agent which in humans exhibits a special tropism for the 
central nervous system (CNS). In nearly 50% of patients affected there is an 
underlying immunological deficiency (AIDS, diabetes mellitus, hematopoietic diseases, 
leprosy, neoplasias, prolonged steroid therapy or other immunosupressive agents). 
It is generally accepted that the simultaneous use of amphotericin-B (AB) intrave-
nously and of 5-flurocytosine (5FC) orally is the treatment of choice 5,6. This regimen, 
however, is far from ideal; almost one third of patients do not respond to the combi-
nation of AB+5FC and there is a high incidence of side effects that sometimes leads 
to the temporary or permanent interruption of the therapy. The pursuit for a less 
toxic and more efficacious drug as an alternative treatment is thus a necessity. 
Ketoconazole (KTZ) is an imidazole derivative with fungistatic properties, which is 
effective in the treatment of systemic mycosis and other fungal infection of the CNS. 
In addition, KTZ seems to be less toxic than the standard therapy with AB+5FC 1.2,4, 
despite its potentiality to provoke liver damage 3 and inhibit steroid synthesis 7. We 
treated two patients suffering from cryptococcosis of the CNS with KTZ at a dose 
of 800mg/day orally for six months uninterrupted and the results obtained are pre-
sented here. 
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Two male inpatients of the neurological department of Hospital de Clinicas, Universi-
dade Federal do Parana, Curitiba, in whom a diagnosis of cryptococcal meningitis was made, 
were treated with KTZ for six months. Both received 800 mg/day orally (400 mg bd.) and 
were assessed on a monthly basis. 
Patient 1 — OB, a 50 year old farmer, with tuberculoid leprosy, presented with) reduced 
visual acuity in the right eye, headache, fever, vomiting and weakness in his left arm and 
leg. These symptoms had commenced 30 days before and had been gradually increasing in 
severity. The neurological examination on admission demonstrated signs of meningeal irrita-
tion, left hemiplegia and right optic nerve atrophy. Cerebral angiography indicated occlusion 
of rigth middle cerebral artery (RMCA); CT scan displayed an ischemic infarction in the 
territory of the RMCA; cerebrospinal fluid (CSF) examination showed a lymphocytic pleocy-
tosis (148 cells/mm3), low glucoce (19mg%) and raised protein (295mg%); Cryptocoecus neo-
formans in Indian ink preparations was positive and the culture was also positive. The patient 
was treated with systemic AB (0.3 mg/Kg per day) and 5FC (150 mg/Kg/day). Due to the 
perseverance of symptoms, after a cumulative dose of 4.6 grams of AB intravenously was 
reached, the administration of AB intrathecally was instituted, with 0.5 mg being given 
every 2 days. This therapy, however, was abandoned after a cumulative dose of 10 mg, be-
cause of the development of urinary retention! land diffuse pain in both legs. An Omaya re-
servoir was then inserted for the intraventricular administration of AB and the patient re-
ceived 0.5 mg every other day to a cumulative dose of 15 mg. Despite improvement in CSF 
parameters treatment was discontinued due to transitory and bilateral oculomotor palsies after 
each application and the occurrence of a tonic-clonic seizure of few seconds after the last dose. 
In spite of the treatment, the patient presented continuous evidence of active fungal infection 
and complained of fierce headache. Consequently, due to the failure of the conventional treat-
ment, a KTZ trial was started with a daily dosage of 800 mg. Clinical improvement was 
noticed during the follow up period. The symptoms gradually lessened and simultaneously 
CSF examination showed progressive normalisation and after 6 month of treatment KTZ was 
tapered off. Recurrence of the clinical symptoms and a positive microscopy were seen a 
month after the suspension of KTZ therapy. Treatment was restarted and his condition stea-
dily improved from then on. The patient remained well for a further 9 months when he was 
lost to follow-up having moved to another State. 
Patient 2 — MLF, a 66 year old cabinet maker, with 3 year history of diabetes mellitus 
treated with chlorpropamide, presented with frontal headache and brief episodes of diplopia. 
Clinical examination on admission recordedi paresis of the right lateral rectus muscle, absence 
of ankles reflexes and a background diabetic retinopathy. CT scan was normal and the CSF 
indicated a lymphocytic pleocytosis (129 cells/mm3), low glucose (46 mg%), and raised protein 
(190 mg%). The Indian ink preparation revealed Crytococcus neformans and the culture was 
positive. A course with systemic AB (0.3mg/Kg/da,y) combined with 5FC (150mg/Kg/day) 
was started. After a cumulative dose of 1.6 grams of AB, a persistent and progressive im-
pairment of renal function was noticed, requiring the withdrawal of the drug in spite of the 
clear-cut clinical improvement. The patient was asymptomatic and the CSF examination showed 
18 cells/mm3, glucoses 65 mg% (blood 148 mg%), protein 78 mg%. Cryptocoecus neoformans was 
seen on microscopy but the culture was negative. No further medication was prescribed and 
the patient was re-evaluated monthly. After a 5 months follow up period in which no symptoms 
were noted, the patient started again to complain of frontal headache and episodic diplopia. 
The clinical examination was unchanged. The CSF analysis at this occasion revealed 26 
cells/mm3, glucose 55mg% (blood 132mg%), protein 93mg%. Cryptocoecus neoformans was 
seen on microscopy but culture was again negative. In spite of the culture result, his symp-
toms were suggestive of a reactivation of the fungal infection and a trial of KTZ was there-
fore initiated. There was progressive clinical improvement and the patient became asympto-
matic after 2 months from commencing KTZ therapy. Treatment was withdrawn after 6 
months and recurrence was not observed during a 3 year follow up period. 
COMMENTS 
In patient 1 the evidence of a positive response of KTZ was clear. The patient 
became asymptomatic and despite the residual signs (left hemiparesis and decreased 
visual acuity in the right eye), he returned to a normal daily life. However, indi-
cation of persistent CNS infection was detected 30 days after the stoppage of therapy. This was construed as a consequence of the fungistatic action of KTZ and this may 
necessitate the administration of the drug for an indefinite period of time. 
Patient 2 was given KTZ on clinical grounds alone having a relapse of his 
symptoms 5 months after the cessation of AB+5FC therapy. The CSF examination 
before the initiation of KTZ showed similar changes to those noticed when the 
AB+5FC treatment was interrupted and the Indian ink test was postive but culture 
was negative. As this diabetic patient already presented signs ot peripheral neuro-
pathy (absence of Achilles reflexes), the visual complaint due to paresis of right 
lateral rectus muscle could also be interpreted as an aftermath of a diabetic VI nerve 
palsy. This, however, would not account for the prevailing symptom of headache 
and it was felt that both symptoms were brought about by the reactivation of the 
fungal infection. The disappearance of these symptoms and the normalisation of the 
CSF during the therapy with KTZ further supports this hypothesis. It cannot be 
certain that the cure was effected by the drug, because the microscopy for Crypto-
coccus neoformans in the Indian ink test was positive but the cultures were negative 
from the commencement. 
Only patient 2 suffered any side effects. He complained of nausea during the 
first two weeks of his treatment, however, this did not require the reduction or 
suspension of the drug. Monthly liver function tests were within normal parameters 
in both patients. 
On the basis of our experience we suggest that KTZ could be useful in CNS 
cryptococcosis in the event of either failure of the standard therapy or when intole-
rable toxic side effects do not allow the continuation of conventional treatment. Its 
fungistatic action, however, may render the administration of the drug imperative for 
an indefinite period of time. 
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